← Back to Search

Ride Share Program for Prostate Cancer Access

N/A
Waitlist Available
Led By Quoc-Dien Trinh, MD,MBA
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Seeking prostate cancer definitive treatment (surgery or radiation) at the Mass General Brigham Prostate Cancer Outreach Clinic
Intermediate-or high-risk prostate cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 90 days of diagnosis
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to reduce disparities in prostate cancer treatment access among Black men, increasing health equity and reducing travel burden.

Who is the study for?
This trial is specifically for Black men with intermediate or high-risk prostate cancer who are seeking surgery or radiation at the Mass General Brigham Prostate Cancer Outreach Clinic. Participants should live in areas of Massachusetts with high travel burdens to medical appointments, or personally report transportation challenges.
What is being tested?
The study is testing a ride share service to see if it helps reduce the difficulty of getting to treatment appointments for prostate cancer patients facing travel hardships. The goal is to improve health equity by making access to care easier.
What are the potential side effects?
Since this trial involves a ride sharing intervention rather than a medical treatment, there are no direct side effects like those associated with drugs or surgical procedures. However, participants may experience issues related to convenience and comfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am looking for a final treatment for prostate cancer, either surgery or radiation, at the Mass General Brigham Prostate Cancer Outreach Clinic.
Select...
My prostate cancer is not low-risk.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 90 days of diagnosis
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 90 days of diagnosis for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants receiving definitive treatment within 90 days of diagnosis
Secondary study objectives
Exit Interview
Rate of Missed appointments

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ride Share ParticipantsExperimental Treatment1 Intervention
Investigators will recruit Black men with intermediate or high-risk PC who are seeking definitive treatment at Mass General Brigham Prostate Cancer Outreach Clinic, as Black men are more likely to report travel burden when accessing care and, therefore, most likely to benefit from ridesharing services. Investigators will implement a pre/post-evaluation design with matched historical controls to estimate the impact of rideshares on reducing missed appointments. Historical controls will be sampled from the pre-intervention period of April 2022 to September 2024 and the post-intervention period between October 2024 and November 2025, where October 2024 represents the initiation of the intervention. Participants who identify as Black, reside in a census tract in Massachusetts, and have been recognized as having a high travel burden based on results from Aim 1 will be eligible to receive the rideshare intervention

Find a Location

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,668 Previous Clinical Trials
11,876,172 Total Patients Enrolled
22 Trials studying Prostate Cancer
32,729 Patients Enrolled for Prostate Cancer
United States Department of DefenseFED
914 Previous Clinical Trials
334,365 Total Patients Enrolled
37 Trials studying Prostate Cancer
8,933 Patients Enrolled for Prostate Cancer
Dana-Farber Cancer InstituteOTHER
1,111 Previous Clinical Trials
358,231 Total Patients Enrolled
76 Trials studying Prostate Cancer
15,631 Patients Enrolled for Prostate Cancer
Quoc-Dien Trinh, MD,MBAPrincipal InvestigatorBrigham and Women's Hospital
~61 spots leftby Dec 2025